论文部分内容阅读
目的观察骨髓瘤患者血清白蛋白浓度的变化,比较减低剂量LMP方案联合α2b-干扰素与标准MPT方案治疗老年多发性骨髓瘤的临床疗效。方法选取2009年1月—2013年12月在我院血液科就诊的老年多发性骨髓瘤患者96例,将其随机分为观察组与对照组,每组48例。观察组患者采取减低剂量LMP方案(雷利度胺、马法兰、泼尼松)加α2b-干扰素化疗;对照组采用标准MPT方案(马法兰,泼尼松,沙利度胺)化疗,在5个疗程后,评价二组的疗效,以及血清白蛋白浓度的变化。结果治疗后观察组血清白蛋白浓度(39.42±5.26)g/L高于对照组(36.81±6.14)g/L,差异有统计学意义(t=2.237,P=0.028)。观察组总有效率85.4%,对照组总有效率56.3%,二组比较差异有统计学意义(χ2=8.521,P=0.004)。结论减低剂量LMP方案联合α2b-干扰素较标准MPT方案治疗老年多发性骨髓瘤疗效更好。
Objective To observe the changes of serum albumin concentration in patients with myeloma, and to compare the clinical efficacy of low-dose LMP regimen with α2b-interferon and standard MPT regimen in the treatment of elderly multiple myeloma. Methods A total of 96 elderly patients with multiple myeloma treated in Department of Hematology from January 2009 to December 2013 were selected and randomly divided into observation group and control group with 48 cases in each group. Patients in the observation group received chemotherapy with reduced-dose LMP regimen (lenalidomide, melphalan, prednisone) plus α2b-interferon and control group with standard MPT regimen (melphalan, prednisone, thalidomide) After the course of treatment, the curative effect of the two groups and the change of serum albumin concentration were evaluated. Results After treatment, the serum albumin concentration of the observation group (39.42 ± 5.26) g / L was significantly higher than that of the control group (36.81 ± 6.14) g / L, with a significant difference (t = 2.237, P = 0.028). The total effective rate was 85.4% in the observation group and 56.3% in the control group. The difference between the two groups was statistically significant (χ2 = 8.521, P = 0.004). CONCLUSIONS: The combination of dose-reducing LMP with α2b-interferon is superior to standard MPT in the treatment of elderly multiple myeloma.